Any current/future new fundraising through debt or equity?

The company is currently comfortable with its net debt to EBITDA ratio of around one times and does not see this as a major concern. They continue to look for bolt-on acquisitions, particularly for their specialty 505(B)(2) franchise, implying potential for additional funding needs aligned with these acquisitions. No explicit mention of immediate or large-scale new fundraising through debt or equity was made. The company expects to manage capital allocation focusing on inorganic growth primarily through bolt-on acquisitions and internal cash generation. De-leveraging plans include using cash g

Any current/future capex/capital investment/strategic investment?

FY27 capex is planned around ₹1,500 crore, reflecting an uptick due to multiple expansion initiatives. (Page 15) Quarterly depreciation is around ₹550 crore, including capitalized licensing fees related to Mirabegron, charged until September 2027. (Page 15) Company continues to look for bolt-on acquisitions, especially to build the Specialty 505(B)(2) franchise and expand portfolio. (Page 19, 17) Focus on investing in new capabilities and platforms, including Specialty business scale-up and international market growth. (Page 17) Commercialization investment for Saroglitazar (Saro) estimated at

Future growth expectations in sales/revenue/volumes?

The US base business is expected to sustain a revenue base around $300-$310 million, with some erosion due to competition (e.g., Mira competition) factored in. Growth may pick up later in the year but remain balanced overall. Specialty business, including 505(B)(2) and rare disease portfolios, is currently small but expected to scale up significantly from FY28 onwards. International markets have shown strong growth (~40% in FY26) with broad-based momentum across regions, expected to continue in the coming years. India formulation business is anticipated to grow 200-400 basis points faste

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 margins expected to be in excess of 24%, considering competition and Saro launch expenses. Specialty business, including 505(B)(2) portfolio, expected to scale up notably from FY28 onwards. Scale-up of biologics/biosimilars and international business (growing 40%+) anticipated to be key growth drivers. Operating profit and EPS expected to improve steadily with bolt-on acquisitions and organic growth. Medical devices business to build momentum over 3-4 years, with profitability improving via synergies. Consumer wellness segment (Comfort Click acquisition) is a fast-growing, EPS-accretive b

Current/ Expected Orderbook/ Pending Orders?

The current orderbook is around $300 to $310 million. Some erosion is expected due to Mira competition, which is factored into the outlook. The orderbook is anticipated to experience typical generic market growth trends, though pressure is expected from competition. Specialty business contribution to the orderbook is currently small but is expected to scale up from FY28 onwards. Overall, the $320 million pool is expected to keep growing but with some erosion from existing contracts.

IN US

Sale is live|00:00:00left today

Zydus Lifesciences LtdQ1 FY26Pharmaceuticals & Biotechnology

Zydus Lifesciences Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,116P/E: 19.9Market Cap: ₹1.0L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→The US base business is expected to sustain a revenue base around $300-$310 million, with some erosion due to competition (e.g., Mira competition) factored in. Growth may pick up later in the year but remain balanced overall.
→Specialty business, including 505(B)(2) and rare disease portfolios, is currently small but expected to scale up significantly from FY28 onwards.
→International markets have shown strong growth (~40% in FY26) with broad-based momentum across regions, expected to continue in the coming years.
→India formulation business is anticipated to grow 200-400 basis points faster than the market due to innovative product launches and stronger therapy focus.
→Biosimilars and biologics to scale meaningfully in global markets over the next 3-4 years, with real scale-up anticipated by FY29-FY30.
→Specialty oncology and supportive care portfolios in the US to grow anchored by upcoming launches and acquisitions like Assertio providing commercial scale.
→Overall, expect continued double-digit growth driven by innovation, inorganic acquisitions, and expanding international presence.

Margin guidance

Category 4

→FY27 margins expected to be in excess of 24%, considering competition and Saro launch expenses.
→Specialty business, including 505(B)(2) portfolio, expected to scale up notably from FY28 onwards.
→Scale-up of biologics/biosimilars and international business (growing 40%+) anticipated to be key growth drivers.
→Operating profit and EPS expected to improve steadily with bolt-on acquisitions and organic growth.
→Medical devices business to build momentum over 3-4 years, with profitability improving via synergies.
→Consumer wellness segment (Comfort Click acquisition) is a fast-growing, EPS-accretive business contributing positively.
→Specialty and rare disease products currently small but projected to become more meaningful and profitable within 3-4 years.
→Continued R&D focus with 8% R&D expense factored into guidance, supporting future pipeline growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company is currently comfortable with its net debt to EBITDA ratio of around one times and does not see this as a major concern.
→They continue to look for bolt-on acquisitions, particularly for their specialty 505(B)(2) franchise, implying potential for additional funding needs aligned with these acquisitions.
→No explicit mention of immediate or large-scale new fundraising through debt or equity was made.
→The company expects to manage capital allocation focusing on inorganic growth primarily through bolt-on acquisitions and internal cash generation.
→De-leveraging plans include using cash generation to reduce net debt post acquisitions like Assertio, with ongoing monitoring of working capital and operational cash flow.
→Overall, no announcement of new debt or equity fundraising was indicated in the transcript; capital strategy is balanced with growth and financial health in mind.

Order book

→The current orderbook is around $300 to $310 million.
→Some erosion is expected due to Mira competition, which is factored into the outlook.
→The orderbook is anticipated to experience typical generic market growth trends, though pressure is expected from competition.
→Specialty business contribution to the orderbook is currently small but is expected to scale up from FY28 onwards.
→Overall, the $320 million pool is expected to keep growing but with some erosion from existing contracts.

Capex plans

Yes

→FY27 capex is planned around ₹1,500 crore, reflecting an uptick due to multiple expansion initiatives. (Page 15)
→Quarterly depreciation is around ₹550 crore, including capitalized licensing fees related to Mirabegron, charged until September 2027. (Page 15)
→Company continues to look for bolt-on acquisitions, especially to build the Specialty 505(B)(2) franchise and expand portfolio. (Page 19, 17)
→Focus on investing in new capabilities and platforms, including Specialty business scale-up and international market growth. (Page 17)
→Commercialization investment for Saroglitazar (Saro) estimated at around $70 million for FY27. (Page 11)
→Additional investments being made in MedTech, CDMO, and international expansion with expectations of scaling over 3-4 years. (Page 11)
→Cost rationalization and efficiency improvements ongoing to offset rising costs from geopolitical and supply chain challenges. (Page 19)

How does Zydus Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zydus Lifesciences Ltd

Rev 2Mar 4

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zydus Lifesciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio